Now showing items 1-3 of 3

    • PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation. 

      Gupta, A; Anjomani-Virmouni, S; Koundouros, N; Dimitriadi, M; Choo-Wing, R; Valle, A; Zheng, Y; Chiu, Y-H; Agnihotri, S; Zadeh, G; Asara, JM; Anastasiou, D; Arends, MJ; Cantley, LC; Poulogiannis, G (2017-03-16)
      PARK2 is a gene implicated in disease states with opposing responses in cell fate determination, yet its contribution in pro-survival signaling is largely unknown. Here we show that PARK2 is altered in over a third of all ...
    • PARK2 loss promotes cancer progression via redox-mediated inactivation of PTEN. 

      Gupta, A; Anjomani-Virmouni, S; Koundouros, N; Poulogiannis, G (2017)
      Cancer and Parkinson disease (PD) derive from distinct alterations in cellular processes, yet there are pathogenic mutations that are unequivocally linked to both diseases. Here we expand on our recent findings that loss ...
    • Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. 

      Wilkerson, PM; Dedes, KJ; Samartzis, EP; Dedes, I; Lambros, MB; Natrajan, R; Gauthier, A; Piscuoglio, S; Töpfer, C; Vukovic, V; Daley, F; Weigelt, B; Reis-Filho, JS (2017-01-24)
      PURPOSE: To determine if models of ovarian clear cell carcinomas (OCCCs) harbouring defects in homologous recombination (HR) DNA repair of double strand breaks (DSBs) are sensitive to cisplatin and/or PARP inhibition. ...